Proteomic characterization of an isolated fraction of synthetic proteasome inhibitor (PSI)-induced inclusions in PC12 cells might offer clues to aggresomes as a cellular defensive response against proteasome inhibition by PSI

BMC Neuroscience

Volumn 11, Issue , 2010, Pages

  Li, Xing'an ^a,b   Zhang, Yingjiu ^b   Xie, Peng ^c   Piao, Jinhua ^a   Hu, Yihong ^a   Chang, Ming ^a   Liu, Tao ^a   Hu, Linsen ^a  

^a JILIN UNIVERSITY   (China)

^b BEIJING UNIVERSITY OF POSTS AND TELECOMMUNICATIONS   (China)

^c CHONGQING MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATASE; ALPHA TUBULIN; BETA TUBULIN; CHAPERONE; COPPER ZINC SUPEROXIDE DISMUTASE; HEAT SHOCK COGNATE PROTEIN 70; HEAT SHOCK PROTEIN 27; HEAT SHOCK PROTEIN 32; HEAT SHOCK PROTEIN 70; PROCOLLAGEN PROLINE 2 OXOGLUTARATE 4 DIOXYGENASE; PROTEASOME; PROTEASOME INHIBITOR; PROTEIN 14 3 3; PROTEIN DISULFIDE ISOMERASE; PROTON TRANSPORTING ADENOSINE TRIPHOSPHATE SYNTHASE; TRYPAN BLUE; TYROSINE 3 MONOOXYGENASE; UBIQUINOL CYTOCHROME C REDUCTASE; VALOSIN CONTAINING PROTEIN; NERVE PROTEIN;

AGGRESOME; ANIMAL CELL; ARTICLE; CELL FRACTIONATION; CELL INCLUSION; CELL STRAIN; CELL SURVIVAL; CONTROLLED STUDY; CYTOCHEMISTRY; ENDOPLASMIC RETICULUM; LEWY BODY; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; MOLECULAR RECOGNITION; NONHUMAN; NUCLEOTIDE SEQUENCE; PROTEIN ANALYSIS; PROTEIN FAMILY; PROTEOMICS; RAT; ANIMAL; BIOSYNTHESIS; DRUG ANTAGONISM; DRUG EFFECT; IMMUNOHISTOCHEMISTRY; METABOLISM; REPRODUCIBILITY; TWO DIMENSIONAL GEL ELECTROPHORESIS;

ANIMALS; CELL SURVIVAL; ELECTROPHORESIS, GEL, TWO-DIMENSIONAL; IMMUNOHISTOCHEMISTRY; INCLUSION BODIES; NERVE TISSUE PROTEINS; PC12 CELLS; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTEOMICS; RATS; REPRODUCIBILITY OF RESULTS;

EID: 77955364974     PISSN: None     EISSN: 14712202     Source Type: Journal    
DOI: 10.1186/1471-2202-11-94     Document Type: Article

References (109)

1. Roth J, Yam GH, Fan J, Hirano K, Gaplovska-Kysela K, Le Fourn V, Guhl B, Santimaria R, Torossi T, Ziak M, Zuber C. Protein quality control: the who's who, the where's and therapeutic escapes. Histochem Cell Biol 2008, 129:163-177. 10.1007/s00418-007-0366-7, 2228381, 18075753.
2. Outeiro TF, Tetzlaff J. Mechanisms of disease II: cellular protein quality control. Semin Pediatr Neurol 2007, 14:15-25. 10.1016/j.spen.2006.11.005, 17331880.
3. Groothuis TA, Dantuma NP, Neefjes J, Salomons FA. Ubiquitin crosstalk connecting cellular processes. Cell Div 2006, 1:21. 10.1186/1747-1028-1-21, 1613237, 17007633.
4. McNaught KS, Olanow CW. Protein aggregation in the pathogenesis of familial and sporadic Parkinson's disease. Neurobiol Aging 2006, 27:530-545. 10.1016/j.neurobiolaging.2005.08.012, 16207501.
5. Segref A, Hoppe T. Think locally: control of ubiquitin-dependent protein degradation in neurons. EMBO Rep 2009, 10:44-50. 10.1038/embor.2008.229, 2613211, 19079132.
6. Garcia-Mata R, Gao YS, Sztul E. Hassles with taking out the garbage: aggravating aggresomes. Traffic 2002, 3:388-396. 10.1034/j.1600-0854.2002.30602.x, 12010457.
7. Forno LS. Neuropathology of Parkinson's disease. J Neuropathol Exp Neurol 1996, 55:259-272. 10.1097/00005072-199603000-00001, 8786384.
8. Ross CA, Poirier MA. Protein aggregation and neurodegenerative disease. Nat Med 2004, (Suppl):S10-17. 10.1038/nm1066, 15272267.
9. Fornai F, Lenzi P, Gesi M, Soldani P, Ferrucci M, Lazzeri G, Capobianco L, Battaglia G, De Blasi A, Nicoletti F, Paparelli A. Methamphetamine produces neuronal inclusions in the nigrostriatal system and in PC12 cells. J Neurochem 2004, 88:114-123. 10.1046/j.1471-4159.2003.02137.x, 14675155.
10. Dev KK, Hofele K, Barbieri S, Buchman VL, van der Putten H. Part II: alpha-synuclein and its molecular pathophysiological role in neurodegenerative disease. Neuropharmacology 2003, 45:14-44. 10.1016/S0028-3908(03)00140-0, 12814657.
11. McNaught KS, Shashidharan P, Perl DP, Jenner P, Olanow CW. Aggresome-related biogenesis of Lewy bodies. Eur J Neurosci 2002, 16:2136-2148. 10.1046/j.1460-9568.2002.02301.x, 12473081.
12. Taylor JP, Tanaka F, Robitschek J, Sandoval CM, Taye A, Markovic-Plese S, Fischbeck KH. Aggresomes protect cells by enhancing the degradation of toxic polyglutamine-containing protein. Hum Mol Genet 2003, 12:749-757. 10.1093/hmg/ddg074, 12651870.
13. Olzmann JA, Li L, Chin LS. Aggresome formation and neurodegenerative diseases: therapeutic implications. Curr Med Chem 2008, 15:47-60. 10.2174/092986708783330692, 18220762.
14. Yew EH, Cheung NS, Choy MS, Qi RZ, Lee AY, Peng ZF, Melendez AJ, Manikandan J, Koay ES, Chiu LL, Ng WL, Whiteman M, Kandiah J, Halliwell B. Proteasome inhibition by lactacystin in primary neuronal cells induces both potentially neuroprotective and pro-apoptotic transcriptional responses: a microarray analysis. J Neurochem 2005, 94:943-956. 10.1111/j.1471-4159.2005.03220.x, 15992382.
15. Peng ZF, Chen MJ, Yap YW, Manikandan J, Melendez AJ, Choy MS, Moore PK, Cheung NS. Proteasome inhibition: an early or late event in nitric oxide-induced neuronal death?. Nitric Oxide 2008, 18:136-145. 10.1016/j.niox.2007.11.002, 18078831.
16. Wang Y, Meriin AB, Zaarur N, Romanova NV, Chernoff YO, Costello CE, Sherman MY. Abnormal proteins can form aggresome in yeast: aggresome-targeting signals and components of the machinery. FASEB J 2009, 23:451-463. 10.1096/fj.08-117614, 2630789, 18854435.
17. Gregersen N. Protein misfolding disorders: pathogenesis and intervention. J Inherit Metab Dis 2006, 29:456-470. 10.1007/s10545-006-0301-4, 16763918.
18. Ebadi M, Pfeiffer RF. Parkinson's disease. Texas (USA): Culinary and Hospitality Industry Publications Services 2005, 132., http://www.chipsbooks.com/parkdis.htm
19. Zhou Y, Gu G, Goodlett DR, Zhang T, Pan C, Montine TJ, Montine KS, Aebersold RH, Zhang J. Analysis of alpha-synuclein-associated proteins by quantitative proteomics. J Biol Chem 2004, 279:39155-39164. 10.1074/jbc.M405456200, 15234983.
20. Leverenz JB, Umar I, Wang Q, Montine TJ, McMillan PJ, Tsuang DW, Jin J, Pan C, Shin J, Zhu D, Zhang J. Proteomic identification of novel proteins in cortical Lewy bodies. Brain Pathol 2007, 17:139-145. 10.1111/j.1750-3639.2007.00048.x, 17388944.
21. Xia Q, Liao L, Cheng D, Duong DM, Gearing M, Lah JJ, Levey AI, Peng J. Proteomic identification of novel proteins associated with Lewy bodies. Front Biosci 2008, 13:3850-3856. 10.2741/2973, 2663966, 18508479.
22. Guimarães de Araújo ME, Huber LA. Subcellular fractionation. Methods Mol Biol 2007, 357:73-85.
23. McNaught KS, Belizaire R, Jenner P, Olanow CW, Isacson O. Selective loss of 20 S proteasome alpha-subunits in the substantia nigra pars compacta in Parkinson's disease. Neurosci Lett 2002, 326:155-158. 10.1016/S0304-3940(02)00296-3, 12095645.
24. Rideout HJ, Larsen KE, Sulzer D, Stefanis L. Proteasomal inhibition leads to formation of ubiquitin/alpha-synuclein-immunoreactive inclusions in PC12 cells. J Neurochem 2001, 78:899-908. 10.1046/j.1471-4159.2001.00474.x, 11520910.
25. Li X, Zhang Y, Hu Y, Chang M, Liu T, Wang D, Zhang Y, Zhang L, Hu L. Chaperone proteins identified from synthetic proteasome inhibitor-induced inclusions in PC12 cells by proteomic analysis. Acta Biochim Biophys Sin (Shanghai) 2008, 40:406-418. 10.1111/j.1745-7270.2008.00416.x, 18465026.
26. Hendzel MJ, Nishioka WK, Raymond Y, Allis CD, Bazett-Jones DP, Th'ng JP. Chromatin condensation is not associated with apoptosis. J Biol Chem 1998, 273:24470-24478. 10.1074/jbc.273.38.24470, 9733739.
27. Wondrak GT, Cervantes-Laurean D, Jacobson EL, Jacobson MK. Histone carbonylation in vivo and in vitro. Biochem J 2000, 351:769-777. 10.1042/0264-6021:3510769, 1221418, 11042133.
28. Tofaris GK, Razzaq A, Ghetti B, Lilley KS, Spillantini MG. Ubiquitination of alpha-synuclein in Lewy bodies is a pathological event not associated with impairment of proteasome function. J Biol Chem 2003, 278:44405-44411. 10.1074/jbc.M308041200, 12923179.
29. Anderson JP, Walker DE, Goldstein JM, de Laat R, Banducci K, Caccavello RJ, Barbour R, Huang J, Kling K, Lee M, Diep L, Keim PS, Shen X, Chataway T, Schlossmacher MG, Seubert P, Schenk D, Sinha S, Gai WP, Chilcote TJ. Phosphorylation of Ser-129 is the dominant pathological modification of alpha-synuclein in familial and sporadic Lewy body disease. J Biol Chem 2006, 281:29739-29752. 10.1074/jbc.M600933200, 16847063.
30. Wang L, Li D, Bao C, You J, Wang Z, Shi Y, Zhang H. Ultrasonic extraction and separation of anthraquinones from Rheum palmatum L. Ultrason Sonochem 2008, 15:738-746. 10.1016/j.ultsonch.2007.12.008, 18280764.
31. Witzmann FA, Arnold RJ, Bai F, Hrncirova P, Kimpel MW, Mechref YS, McBride WJ, Novotny MV, Pedrick NM, Ringham HN, Simon JR. A proteomic survey of rat cerebral cortical synaptosomes. Proteomics 2005, 5:2177-2201. 10.1002/pmic.200401102, 1472619, 15852343.
32. Jin BF, He K, Wang HX, Wang J, Zhou T, Lan Y, Hu MR, Wei KH, Yang SC, Shen BF, Zhang XM. Proteomic analysis of ubiquitin-proteasome effects: insight into the function of eukaryotic initiation factor 5A. Oncogene 2003, 22:4819-4830. 10.1038/sj.onc.1206738, 12894223.
33. Mimnaugh EG, Xu W, Vos M, Yuan X, Isaacs JS, Bisht KS, Gius D, Neckers L. Simultaneous inhibition of hsp 90 and the proteasome promotes protein ubiquitination, causes endoplasmic reticulum-derived cytosolic vacuolization, and enhances antitumor activity. Expert Rev Proteomics 2004, 1:207-217. 10.1586/14789450.1.2.207, 15966815.
34. Kakhniashvili DG, Griko NB, Bulla LA, Goodman SR. The proteomics of sickle cell disease: profiling of erythrocyte membrane proteins by 2D-DIGE and tandem mass spectrometry. Exp Biol Med (Maywood) 2005, 230:787-792.
35. Nakashima S, Ikuta F. Tyrosine hydroxylase protein in Lewy bodies of parkinsonian and senile brains. J Neurol Sci 1984, 66:91-96. 10.1016/0022-510X(84)90144-8, 6151589.
36. Ostrerova N, Petrucelli L, Farrer M, Mehta N, Choi P, Hardy J, Wolozin B. alpha-Synuclein shares physical and functional homology with 14-3-3 proteins. J Neurosci 1999, 19:5782-5791.
37. Alim MA, Hossain MS, Arima K, Takeda K, Izumiyama Y, Nakamura M, Kaji H, Shinoda T, Hisanaga S, Ueda K. Tubulin seeds alpha-synuclein fibril formation. J Biol Chem 2002, 277:2112-2117. 10.1074/jbc.M102981200, 11698390.
38. Hayashida K, Oyanagi S, Mizutani Y, Yokochi M. An early cytoplasmic change before Lewy body maturation: an ultrastructural study of the substantia nigra from an autopsy case of juvenile parkinsonism. Acta Neuropathol 1993, 85:445-448. 10.1007/BF00334457, 8480516.
39. Gai WP, Yuan HX, Li XQ, Power JT, Blumbergs PC, Jensen PH. In situ and in vitro study of colocalization and segregation of alpha-synuclein, ubiquitin, and lipids in Lewy bodies. Exp Neurol 2000, 166:324-333. 10.1006/exnr.2000.7527, 11085897.
40. Shibata N, Hirano A, Kobayashi M, Sasaki S, Kato T, Matsumoto S. Cu/Zn superoxide dismutase-like immunoreactivity in Lewy body-like inclusions of sporadic amyotrophic lateral sclerosis. Neurosci Lett 1994, 179:149-152. 10.1016/0304-3940(94)90956-3, 7845611.
41. Nishiyama K, Murayama S, Shimizu J, Ohya Y, Kwak S, Asayama K, Kanazawa I. Cu/Zn superoxide dismutase-like immunoreactivity is present in Lewy bodies from Parkinson disease: a light and electron microscopic immunocytochemical study. Acta Neuropathol 1995, 89:471-474. 10.1007/BF00571500, 7676802.
42. Ii K, Ito H, Tanaka K, Hirano A. Immunocytochemical co-localization of the proteasome in ubiquitinated structures in neurodegenerative diseases and the elderly. J Neuropathol Exp Neurol 1997, 56:125-131. 10.1097/00005072-199702000-00002, 9034365.
43. Outeiro TF, Klucken J, Strathearn KE, Liu F, Nguyen P, Rochet JC, Hyman BT, McLean PJ. Small heat shock proteins protect against alpha-synuclein-induced toxicity and aggregation. Biochem Biophys Res Commun 2006, 351:631-638. 10.1016/j.bbrc.2006.10.085, 1934426, 17081499.
44. Schipper HM, Liberman A, Stopa EG. Neural heme oxygenase-1 expression in idiopathic Parkinson's disease. Exp Neurol 1998, 50:60-68.
45. Richard M, Biacabe AG, Streichenberger N, Ironside JW, Mohr M, Kopp N, Perret-Liaudet A. Immunohistochemical localization of 14.3.3 zeta protein in amyloid plaques in human spongiform encephalopathies. Acta Neuropathol 2003, 105:296-302.
46. Kaneko K, Hachiya NS. The alternative role of 14-3-3 zeta as a sweeper of misfolded proteins in disease conditions. Med Hypotheses 2006, 67:169-171. 10.1016/j.mehy.2006.01.019, 16516399.
47. Imai Y, Soda M, Murakami T, Shoji M, Abe K, Takahashi R. A product of the human gene adjacent to parkin is a component of Lewy bodies and suppresses Pael receptor-induced cell death. J Biol Chem 2003, 278:51901-51910. 10.1074/jbc.M309655200, 14532270.
48. Hirabayashi M, Inoue K, Tanaka K, Nakadate K, Ohsawa Y, Kamei Y, Popiel AH, Sinohara A, Iwamatsu A, Kimura Y, Uchiyama Y, Hori S, Kakizuka A. VCP/p97 in abnormal protein aggregates, cytoplasmic vacuoles, and cell death, phenotypes relevant to neurodegeneration. Cell Death Differ 2001, 8:977-984. 10.1038/sj.cdd.4400907, 11598795.
49. Rideout HJ, Stefanis L. Proteasomal inhibition-induced inclusion formation and death in cortical neurons require transcription and ubiquitination. Mol Cell Neurosci 2002, 21:223-238. 10.1006/mcne.2002.1173, 12401444.
50. Fornai F, Lenzi P, Gesi M, Ferrucci M, Lazzeri G, Busceti CL, Ruffoli R, Soldani P, Ruggieri S, Alessandri MG, Paparelli A. Fine structure and biochemical mechanisms underlying nigrostriatal inclusions and cell death after proteasome inhibition. J Neurosci 2003, 23:8955-8966.
51. Lang-Rollin I, Maniati M, Jabado O, Vekrellis K, Papantonis S, Rideout HJ, Stefanis L. Apoptosis and the conformational change of Bax induced by proteasomal inhibition of PC12 cells are inhibited by bcl-xL and bcl-2. Apoptosis 2005, 10:809-820. 10.1007/s10495-005-0378-5, 16133871.
52. Zhang L, Chang M, Li H, Hou S, Zhang Y, Hu Y, Han W, Hu L. Proteomic changes of PC12 cells treated with proteasomal inhibitor PSI. Brain Res 2007, 1153:196-203. 10.1016/j.brainres.2007.03.073, 17490626.
53. Tse DC, McCreery RL, Adams RN. Potential oxidative pathways of brain catecholamines. J Med Chem 1976, 19:37-40. 10.1021/jm00223a008, 1246050.
54. Keller JN, Dimayuga E, Chen Q, Thorpe J, Gee J, Ding Q. Autophagy, proteasomes, lipofuscin, and oxidative stress in the aging brain. Int J Biochem Cell Biol 2004, 36:2376-2391. 10.1016/j.biocel.2004.05.003, 15325579.
55. Pigeon D, Ferrara P, Gros F, Thibault J. Rat pheochromocytoma tyrosine hydroxylase is phosphorylated on serine 40 by an associated protein kinase. J Biol Chem 1987, 262:6155-6158.
56. Peng X, Tehranian R, Dietrich P, Stefanis L, Perez RG. Alpha-synuclein activation of protein phosphatase 2A reduces tyrosine hydroxylase phosphorylation in dopaminergic cells. J Cell Sci 2005, 118:3523-3530. 10.1242/jcs.02481, 16030137.
57. Døskeland AP, Flatmark T. Ubiquitination of soluble and membrane-bound tyrosine hydroxylase and degradation of the soluble form. Eur J Biochem 2002, 269:1561-1569. 10.1046/j.1432-1033.2002.02808.x, 11874472.
58. Lopez Verrilli MA, Pirola CJ, Pascual MM, Dominici FP, Turyn D, Gironacci MM. Angiotensin-(1-7) through AT receptors mediates tyrosine hydroxylase degradation via the ubiquitin-proteasome pathway. J Neurochem 2009, 109:326-335. 10.1111/j.1471-4159.2009.05912.x, 19183250.
59. Muratani M, Tansey WP. How the ubiquitin-proteasome system controls transcription. Nat Rev Mol Cell Biol 2003, 4:192-201. 10.1038/nrm1049, 12612638.
60. Zimmermann J, Erdmann D, Lalande I, Grossenbacher R, Noorani M, Fürst P. Proteasome inhibitor induced gene expression profiles reveal overexpression of transcriptional regulators ATF3, GADD153 and MAD1. Oncogene 2000, 19:2913-2920. 10.1038/sj.onc.1203606, 10871842.
61. Yu ZX, Li SH, Nguyen HP, Li XJ. Huntingtin inclusions do not deplete polyglutamine-containing transcription factors in HD mice. Hum Mol Genet 2002, 11:905-914. 10.1093/hmg/11.8.905, 11971872.
62. Rajan RS, Illing ME, Bence NF, Kopito RR. Specificity in intracellular protein aggregation and inclusion body formation. Proc Natl Acad Sci USA 2001, 98:13060-13065. 10.1073/pnas.181479798, 60824, 11687604.
63. Redpath NT, Foulstone EJ, Proud CG. Regulation of translation elongation factor-2 by insulin via a rapamycin-sensitive signalling pathway. EMBO J 1996, 15:2291-2297. 450154, 8641294.
64. Arora S, Yang JM, Hait WN. Identification of the ubiquitin-proteasome pathway in the regulation of the stability of eukaryotic elongation factor-2 kinase. Cancer Res 2005, 65:3806-3810. 10.1158/0008-5472.CAN-04-4036, 15867377.
65. Ren Y, Zhao J, Feng J. Parkin binds to alpha/beta tubulin and increases their ubiquitination and degradation. J Neurosci 2003, 23:3316-3324. 1876717, 12716939.
66. Domingues AF, Arduíno DM, Esteves AR, Swerdlow RH, Oliveira CR, Cardoso SM. Mitochondria and ubiquitin-proteasomal system interplay: relevance to Parkinson's disease. Free Radic Biol Med 2008, 45:820-805. 10.1016/j.freeradbiomed.2008.06.007, 18619530.
67. Sullivan PG, Dragicevic NB, Deng JH, Bai Y, Dimayuga E, Ding Q, Chen Q, Bruce-Keller AJ, Keller JN. Proteasome inhibition alters neural mitochondrial homeostasis and mitochondria turnover. J Biol Chem 2004, 279:20699-20707. 10.1074/jbc.M313579200, 14742431.
68. Malkus KA, Tsika E, Ischiropoulos H. Oxidative modifications, mitochondrial dysfunction, and impaired protein degradation in Parkinson's disease: how neurons are lost in the Bermuda triangle. Mol Neurodegener 2009, 4:24. 10.1186/1750-1326-4-24, 2701947, 19500376.
69. Muqit MM, Abou-Sleiman PM, Saurin AT, Harvey K, Gandhi S, Deas E, Eaton S, Payne Smith MD, Venner K, Matilla A, Healy DG, Gilks WP, Lees AJ, Holton J, Revesz T, Parker PJ, Harvey RJ, Wood NW, Latchman DS. Altered cleavage and localization of PINK1 to aggresomes in the presence of proteasomal stress. J Neurochem 2006, 98:156-169. 10.1111/j.1471-4159.2006.03845.x, 16805805.
70. McBride WH, Iwamoto KS, Syljuasen R, Pervan M, Pajonk F. The role of the ubiquitin/proteasome system in cellular responses to radiation. Oncogene 2003, 22:5755-5773. 10.1038/sj.onc.1206676, 12947384.
71. Noor R, Mittal S, Iqbal J. Superoxide dismutase--applications and relevance to human diseases. Med Sci Monit 2002, 8:210-215.
72. Kang JH, Kim KS. Enhanced oligomerization of the alpha-synuclein mutant by the Cu,Zn-superoxide dismutase and hydrogen peroxide system. Mol Cells 2003, 15:87-93.
73. Lee MH, Hyun DH, Jenner P, Halliwell B. Effect of proteasome inhibition on cellular oxidative damage, antioxidant defences and nitric oxide production. J Neurochem 2001, 78:32-41. 10.1046/j.1471-4159.2001.00416.x, 11432971.
74. Alexandrova A, Petrov L, Georgieva A, Kirkova M, Kukan M. Effects of proteasome inhibitor, MG132, on proteasome activity and oxidative status of rat liver. Cell Biochem Funct 2008, 26:392-398. 10.1002/cbf.1459, 18236383.
75. Choi J, Rees HD, Weintraub ST, Levey AI, Chin LS, Li L. Oxidative modifications and aggregation of Cu,Zn-superoxide dismutase associated with Alzheimer and Parkinson diseases. J Biol Chem 2005, 280:11648-11655. 10.1074/jbc.M414327200, 15659387.
76. Thorpe JA, Christian PA, Schwarze SR. Proteasome inhibition blocks caspase-8 degradation and sensitizes prostate cancer cells to death receptor-mediated apoptosis. Prostate 2008, 68:200-209. 10.1002/pros.20706, 18076022.
77. Sun F, Kanthasamy A, Song C, Yang Y, Anantharam V, Kanthasamy AG. Proteasome inhibitor-induced apoptosis is mediated by positive feedback amplification of PKCdelta proteolytic activation and mitochondrial translocation. J Cell Mol Med 2008, 12:2467-2481. 10.1111/j.1582-4934.2008.00293.x, 18298651.
78. Trimmer PA, Borland MK, Keeney PM, Bennett JP, Parker WD. Parkinson's disease transgenic mitochondrial cybrids generate Lewy inclusion bodies. J Neurochem 2004, 88:800-812. 10.1046/j.1471-4159.2003.02168.x, 14756800.
79. Wojcik C, Di Napoli M. Ubiquitin-proteasome system and proteasome inhibition: new strategies in stroke therapy. Stroke 2004, 35:1506-1518. 10.1161/01.STR.0000126891.93919.4e, 15118168.
80. Fuchs D, Berges C, Opelz G, Daniel V, Naujokat C. Increased expression and altered subunit composition of proteasomes induced by continuous proteasome inhibition establish apoptosis resistance and hyperproliferation of Burkitt lymphoma cells. J Cell Biochem 2008, 103:270-283. 10.1002/jcb.21405, 17516511.
81. Lee CS, Tee LY, Warmke T, Vinjamoori A, Cai A, Fagan AM, Snider BJ. A proteasomal stress response: pre-treatment with proteasome inhibitors increases proteasome activity and reduces neuronal vulnerability to oxidative injury. J Neurochem 2004, 91:996-1006. 10.1111/j.1471-4159.2004.02813.x, 15525353.
82. Meiners S, Heyken D, Weller A, Ludwig A, Stangl K, Kloetzel PM, Krüger E. Inhibition of proteasome activity induces concerted expression of proteasome genes and de novo formation of Mammalian proteasomes. J Biol Chem 2003, 278:21517-21525. 10.1074/jbc.M301032200, 12676932.
83. Seo H, Sonntag KC, Isacson O. Generalized brain and skin proteasome inhibition in Huntington's disease. Ann Neurol 2004, 56:319-328. 10.1002/ana.20207, 15349858.
84. McNaught KS, Jackson T, JnoBaptiste R, Kapustin A, Olanow CW. Proteasomal dysfunction in sporadic Parkinson's disease. Neurology 2006, 66:S37-49. 10.1212/01.wnl.0000221745.58886.2e, 16717251.
85. Mandel S, Grunblatt E, Riederer P, Amariglio N, Jacob-Hirsch J, Rechavi G, Youdim MB. Gene expression profiling of sporadic Parkinson's disease substantia nigra pars compacta reveals impairment of ubiquitin-proteasome subunits, SKP1A, aldehyde dehydrogenase, and chaperone HSC-70. Ann N Y Acad Sci 2005, 1053:356-375. 10.1196/annals.1344.031, 16179542.
86. Meimaridou E, Gooljar SB, Chapple JP. From hatching to dispatching: the multiple cellular roles of the Hsp70 molecular chaperonen machinery. J Mol Endocrinol 2009, 42:1-9. 10.1677/JME-08-0116, 18852216.
87. Germain D. Ubiquitin-dependent and -independent mitochondrial protein quality controls: implications in ageing and neurodegenerative diseases. Mol Microbiol 2008, 70:1334-1341. 10.1111/j.1365-2958.2008.06502.x, 19019155.
88. Bian Q, Fernandes AF, Taylor A, Wu M, Pereira P, Shang F. Expression of K6W-ubiquitin in lens epithelial cells leads to upregulation of a broad spectrum of molecular chaperones. Mol Vis 2008, 14:403-412. 2268857, 18334961.
89. Hayes SA, Dice JF. Roles of molecular chaperones in protein degradation. J Cell Biol 1996, 132:255-258. 10.1083/jcb.132.3.255, 2120725, 8636205.
90. Morimoto RI. Proteotoxic stress and inducible chaperone networks in neurodegenerative disease and aging. Genes Dev 2008, 22:1427-1438. 10.1101/gad.1657108, 2732416, 18519635.
91. Slavotinek AM, Biesecker LG. Unfolding the role of chaperones and chaperonnins in human disease. Trend Genet 2001, 17:528-535.
92. Ni M, Lee AS. ER chaperones in mammalian development and human diseases. FEBS Lett 2007, 581:3641-3651. 10.1016/j.febslet.2007.04.045, 2040386, 17481612.
93. Junn E, Lee SS, Suhr UT, Mouradian MM. Parkin accumulation in aggresomes due to proteasome impairment. J Biol Chem 2002, 277:47870-47877. 10.1074/jbc.M203159200, 12364339.
94. Ito H, Kamei K, Iwamoto I, Inaguma Y, García-Mata R, Sztul E, Kato K. Inhibition of proteasomes induces accumulation, phosphorylation, and recruitment of HSP27 and alphaB-crystallin to aggresomes. J Biochem 2002, 131:593-603.
95. Abou-Sleiman PM, Muqit MM, Wood NW. Expanding insights of mitochondrial dysfunction in Parkinson's disease. Nat Rev Neurosci 2006, 7(3):207-219. 10.1038/nrn1868, 16495942.
96. Koivu J, Myllyla R, Helaakoski T, Pihlajaniemi T, Tasanen K, Kivirikko KI. A single polypeptide acts both as the beta subunit of prolyl 4-hydroxylase and as a protein disulfide-isomerase. J Biol Chem 1987, 262:6447-6449.
97. Pajunen L, Jones TA, Goddard A, Sheer D, Solomon E, Pihlajaniemi T, Kivirikko KI. Regional assignment of the human gene coding for a multifunctional polypeptide (P4HB) acting as the beta-subunit of prolyl 4-hydroxylase and the enzyme protein disulfide isomerase to 17q25. Cytogenet Cell Genet 1991, 56:165-168. 10.1159/000133078, 1647289.
98. Hatahet F, Ruddock LW. Substrate recognition by the protein disulfide isomerases. FEBS J 2007, 274:5223-5234. 10.1111/j.1742-4658.2007.06058.x, 17892489.
99. Molinari M, Galli C, Piccaluga V, Pieren M, Paganetti P. Sequential assistance of molecular chaperones and transient formation of covalent complexes during protein degradation from the ER. J Cell Biol 2002, 158:247-257. 10.1083/jcb.200204122, 2173128, 12119363.
100. Conn KJ, Gao W, McKee A, Lan MS, Ullman MD, Eisenhauer PB, Fine RE, Wells JM. Identification of the protein disulfide isomerase family member PDIp in experimental Parkinson's disease and Lewy body pathology. Brain Res 2004, 1022:164-172. 10.1016/j.brainres.2004.07.026, 15353226.
101. Ribble D, Goldstein NB, Norris DA, Shellman YG. A simple technique for quantifying apoptosis in 96-well plates. BMC Biotechnol 2005, 5:12. 10.1186/1472-6750-5-12, 1142306, 15885144.
102. Xu Q, Kanthasamy AG, Reddy MB. Neuroprotective effect of the natural iron chelator, phytic acid in a cell culture model of Parkinson's disease. Toxicology 2008, 245:101-108. 10.1016/j.tox.2007.12.017, 18255213.
103. Kikuchi S, Shinpo K, Tsuji S, Takeuchi M, Yamagishi S, Makita Z, Niino M, Yabe I, Tashiro K. Effect of proteasome inhibitor on cultured mesencephalic dopaminergic neurons. Brain Res 2003, 964:228-236. 10.1016/S0006-8993(02)04030-1, 12576183.
104. Fan HM, Yang L, Xie QF, Han XY, Wu M, Zhang FC, Yao CL, Li G, Gao ZL. Hepatitis B virus × protein suppressing adriamycin-induced apoptosis of HepG2 cells. Zhonghua Gan Zang Bing Za Zhi 2008, 16:25-28.
105. Lee HJ, Lee SJ. Characterization of cytoplasmic alpha-synuclein aggregates. Fibril formation is tightly linked to the inclusion-forming process in cells. J Biol Chem 2002, 277:48976-48983. 10.1074/jbc.M208192200, 12351642.
106. Jones AR, Gibson F. An update on data standards for gel electrophoresis. Proteomics 2007, 7(Suppl 1):35-40. 10.1002/pmic.200700171, 17893862.
107. Taylor CF, Paton NW, Lilley KS, Binz PA, Julian RK, Jones AR, Zhu W, Apweiler R, Aebersold R, Deutsch EW, Dunn MJ, Heck AJ, Leitner A, Macht M, Mann M, Martens L, Neubert TA, Patterson SD, Ping P, Seymour SL, Souda P, Tsugita A, Vandekerckhove J, Vondriska TM, Whitelegge JP, Wilkins MR, Xenarios I, Yates JR, Hermjakob H. The minimum information about a proteomics experiment (MIAPE). Nat Biotechnol 2007, 25:887-893. 10.1038/nbt1329, 17687369.
108. Colinge J. Peptide fragment intensity statistical modeling. Anal Chem 2007, 79:7286-7290. 10.1021/ac070488n, 17713966.
109. Grimmer C, Balbus N, Lang U, Aigner T, Cramer T, Müller L, Swoboda B, Pfander D. Regulation of type II collagen synthesis during osteoarthritis by prolyl-4-hydroxylases: possible influence of low oxygen levels. J Pathol 2006, 169:491-502.